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Disease activity indexAbstract Aim of the work: Growth arrest-speciﬁc protein 6 (Gas6) and its soluble tyrosine kinase
receptor sAxl are known to have antiapoptotic function which may be implicated in systemic lupus
erythematosus (SLE) pathogenesis. We aimed to assess serum levels of GAS6 and its receptor sAxl
in SLE patients and to correlate these levels with disease activity index and renal involvement.
Patients and methods: Gas6 and sAxl were measured by enzyme linked immunosorbent assay
(ELISA) in sera obtained from 50 female patients with SLE and 40 healthy age-matched females
serving as controls. Disease activity was calculated according to the SLE disease activity index
(SLEDAI).
Results: Serum levels of Gas6 and sAxl were signiﬁcantly increased in patients with SLE in com-
parison to controls (p< 0.001). Serum Gas6 levels increased signiﬁcantly in active SLE patients
and lupus nephritis patients (p< 0.001). Serum levels of Gas6 correlated positively with SLEDAI,
double-stranded DNA titers and proteinuria. In addition, there was a signiﬁcant negative correla-
tion between Gas6 serum levels and both C3 and C4; while, serum sAxl levels did not show these
correlations.
Conclusions: Gas6 and sAxl may have a role in the pathogenesis of SLE. Increased serum Gas6
level may be an important risk factor for the development and severity of lupus nephritis. So, Gas6
may have a potential role to serve as a disease activity marker and may have a role as a therapeutic
target for SLE.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
that may result from disturbed tolerance to self antigens and
development of auto-antibodies leading to the formation of
immune complexes [1]. These immune deposits in the tissues
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cade and recruiting inﬂammatory cells [2]. Although the exact
etiology is not known, one of the possible triggers of this
autoimmune reaction is the defective clearance of apoptotic
cells [3,4].
Under normal circumstances, apoptotic cells are engulfed
by macrophages and other phagocytic cells [5]. This provides
a clearance of possible auto-antigens in the early phase of cell
death without inducing inﬂammation or the immune response.
In SLE, however, the clearance of apoptotic cells by macro-
phages is impaired, which may allow apoptotic cells to serve
as immunogens for the induction of autoreactive T and B cells
and drive the production of auto-antibodies [6]. The reasons
for the defective clearance of apoptotic cells in SLE are not
clear [5].
Macrophages recognize apoptotic cells through an array
of surface receptors that are present on the macrophages
and dendritic cells. These tyrosine kinase receptors as tyro
3, axl, and mer of the TAM family may play an impor-
tant role in the phagocytosis or clearance of apoptotic
cells [7].
Growth arrest-speciﬁc protein 6 (Gas6), a 75 kD multi-
modular vitamin K-dependent protein, is a similar protein to
plasma anticoagulant protein S. Gas6 is expressed in many tis-
sues, including capillary endothelial cells, vascular smooth
muscle cells, and bone marrow cells. It was recognized as a
growth factor-like molecule, as it interacted with tyrosine
kinase receptors (TKR) of the TAM family [8]. TAM receptors
undergo a proteolytic processing in the cell membrane, leading
to increased plasma circulating levels of extracellular frag-
ments of the receptors (soluble receptors). So, the mem-
brane-bound Axl can be shed from the cell membrane as a
result of proteolysis. These forms have been shown to interact
with the ligands, modifying their function [9,10]. Soluble forms
of Axl (sAxl) which consist of the extracellular region of the
protein and the ligand Gas6 are present in plasma at low
concentrations. They increase in response to acute phase
reactions [11].
Apoptotic cells express phosphatidylserine (PS) on their
surface, which bind directly to phagocytes via receptors such
as several soluble proteins, including the TAM receptor
ligands Gas6 and protein S [12]. In this process, a TAM
ligand, Gas6, serves as a ‘‘bridging molecule’’ that physically
links a TAM receptor, generally Mer or Axl, expressed on
the surface of the phagocyte, to PS, on the surface of the
apoptotic cell that will be engulfed [13]. Also, the Gas6/
TAM system regulates an intriguing mix of processes,
including cell survival and proliferation, cell adhesion and
migration, blood clot stabilization, and inﬂammatory cyto-
kine release. There is evidence that Gas6 has a pivotal role
in endothelial cell (EC) activation and participates in the
interactions between ECs, platelets, and leukocytes during
inﬂammation [14].
Therefore, it is reasonable to hypothesize that one of the
TAM receptor families (Axl) and one of its ligands, Gas6
might have an important role in the pathogenesis of SLE.
So, the aim of the present study was to assess serum levels of
Gas6 and its soluble tyrosine kinase receptor sAxl in SLE
patients in comparison to healthy controls and to correlate
those levels with SLE disease activity index and renal
involvement.2. Patients and methodsFifty female SLE patients were selected from those presenting
to the Rheumatology Department and Rheumatology and
Rehabilitation outpatient Clinic of Ain Shams University Hos-
pital. SLE patients were all fulﬁlling the updated American
College of Rheumatology (ACR) revised criteria for the classi-
ﬁcation of SLE [15]. Patients with other inﬂammatory diseases,
infections, malignancy or oral anticoagulant therapy were
excluded.
The control group consisted of 40 healthy, age-matched
females. The study protocol was in accordance with the Hel-
sinki declaration of human rights, and was approved by the
local Ethics Committee. The written informed consent from
each patient and control was obtained.
All patients were subjected to the following:
2.1 Full history taking and thorough physical examination.
2.2 Assessment of disease activity by using the systemic
lupus erythematosis disease activity index (SLEDAI)
[16]. A patient with SLEDAI < 6 is considered inactive
SLE and patients are considered as active SLE when
SLEDAIP 6.
2.3 Assessment of renal involvement: SLE patients were
also subdivided according to presence or absence of
lupus nephritis into another two subgroups. Lupus
nephritis was deﬁned as having histopathological
evidence of immune complex-mediated glomerulone-
phritis, plus the current renal portion of SLEDAI. This
consists of the four kidney-related items of the SLEDAI
which are hematuria (>5 RBCs/HPF after exclusion of
stone, infection or other causes), pyuria (>5 WBCs/
HPF after exclusion of infection), proteinuria (>0.5 g/
24 h, either of new onset or recent increase of more than
0.5 g/24 h) and urinary casts (granular or red blood cell)
[16].
2.4 Laboratory testing– Complete blood count (CBC) using coulter counter
(Coulter LH 750 analyzer).
– Erythrocyte sedimentation rate (ESR; in mm/1st h-
our) by the Westergren method.
– Quantitative measurement of serum anti-double str-
anded-DNA (Anti-dsDNA) antibodies was deter-
mined by EIA (anti-dsDNA Kit, ORGENTEC
Diagnostika GmbH ELISA kit (Carl-Zeiss Strarabe
49, Germany).
– Levels of complement 3 and 4 (C3 and C4) were
measured by nephelometric method using a Mini-
neph human C3 and C4 kit (Binding site Group
Ltd., Birmingham, UK).
– Serum creatinine on a synchron X9 (Beckman
instrument Inc., USA).
– Measurement of protein creatinine ratio (Pr/Cr).
– Complete urine analysis.2.5 Measurement of Gas6 and sAxl was performed to all
patients and controls by commercially available ELISA
kits supplied by Gas6, WKEA Med supplies corpora-
tion, NY, USA and sAxl, Ray Biotech Inc., GA,
USA, respectively.
Table 2 Laboratory data of systemic lupus erythematosus
patients.
SLE patients (n= 50) 25th–75th percentiles Median
Hb (g/dL) 7–13.8 10.5
WBC (·103/mm3) 3.77–7.35 5.4
Platelets (·103/mm3) 157–278 200
ESR (mm/h) 8–89 41.5
Creatinine (mg/dL) 0.7–1.9 1.3
Urinary Pr/Cr ratio 0.2–5.1 0.8
C3 (mg/dL) 88–165 120
C4 (mg/dL) 40–68 56
Anti-ds DNA antibodies (U/l) 15–24.5 18.4
SLE: systemic lupus erythematosus; Hb: hemoglobin; WBC: white
blood cells; ESR: erythrocyte sedimentation rate; Pr/C: protein /
creatinine ratio; C3: complement 3; C4: complement 4.
Serum growth arrest speciﬁc protein 6 and its receptor (Axl) in SLE patients 63Statistical analysis: IBM SPSS statistical software package
(V. 21.0, IBM Corp., USA, 2012) was used for data analysis.
Data were expressed as range (minimum–maximum), mean
and standard deviation (SD) for quantitative parametric data,
and median and 25th and 75th percentiles for quantitative non
parametric data. Nominal data were expressed as frequency
and percentage. Comparison between two independent groups
of numerical parametric data was done using Student’s t-test
and Mann–Whitney test for non parametric data. Pearson cor-
relation coefﬁcient test was done to study the correlation
between two quantitative variables. Receiver operator charac-
teristic (ROC) procedures identiﬁed optimal cut-off values for
Gas6 to differentiate between SLE patients and controls,
active and inactive SLE patients and patients with and without
lupus nephritis. Probability of error at <0.05 was considered
signiﬁcant and highly signiﬁcant at <0.001.
3. Results
This study included ﬁfty female patients with SLE. Forty
healthy female subjects served as the control group. The
patients’ age ranged from 18 to 56 years, with a mean of
32.24 ± 9.15 years, this was matched with the age of the con-
trol group that ranged from 20 to 54 years, with a mean age of
31.5 ± 8.91 years. The disease duration ranged from 0.5 to
13 years; with a mean of 4.1 + 3.5 years. The age of onset of
the disease ranged from 17.5 to 44 years with a mean of
30.5 + 7.5 years.
SLE disease activity index ranged in SLE patients from 1 to
12 with a median of 6. SLE patients were subdivided according
to the disease activity index into two groups: inactive SLE group
including 18 patients (SLEDAI < 6) and active SLE group
including 32 patients (SLEDAIP 6). SLE Patients were also
subdivided according to presence or absence of lupus nephritis
into another two subgroups: lupus nephritis group (n= 25)
and kidney sparing SLE patient group (n= 25). Clinical and
laboratory data of SLE patients are depicted in Tables 1 and 2.Table 1 Percentage of clinical and laboratory data in systemic
lupus erythematosus patients.
SLE patients (n= 50) Percentage (%)
Arthritis 22
Oral ulcers 20
New rash 12
Alopecia 10
Fever 8
Pleurisy 6
Vasculitis 4
Headache 2
Visual disturbance 0
Psychosis 0
Proteinuria 50
Low complement 26
Increased anti-ds-DNA antibodies 22
Leucopenia 16
Thrombocytopenia 8
Urinary casts 8
Hematuria 6
Pyuria 6
SLE: systemic lupus erythematosus.Serum Gas6 and sAxl levels ranged from 26.5–49 ng/ml and
24.1–103.8 ng/ml respectively in SLE patients. When
compared with a range of 3–9 ng/ml and 0.3–0.9 ng/ml in the
control group, there was a highly signiﬁcant elevation in serum
Gas6 and sAxl levels in SLE patients versus controls
(p< 0.001) (Table 3). Serum Gas6 levels increased signiﬁ-
cantly in active SLE patients and lupus nephritis patients in
comparison to inactive SLE patients and patients without
renal involvement, respectively (p< 0.001). While, there were
no signiﬁcant differences regarding serum levels of sAxl when
comparing these groups (Table 3, Figs. 1 and 2).
In SLE patients, serum Gas6 levels showed signiﬁcant posi-
tive correlation with SLEDAI, ESR, anti-ds-DNA titre, pro-
teinuria and negative correlation with serum C3 and C4 levels
(p< 0.001), while, there were no signiﬁcant correlations
between serum Gas6 levels and both disease duration and age
of onset of the disease (p> 0.05). There were no signiﬁcant cor-
relations between serum sAxl levels and all previous parameters
(p> 0.05). Also, there were no signiﬁcant correlations between
serum sAxl levels and serum GAS6 levels (p> 0.05) (Table 4).
Receiver-operating characteristic (ROC) curve was applied
to obtain the most sensitive and speciﬁc cut off level for Gas6
in order to discriminate active SLE patients (n= 32) from
inactive patients (n= 18). Serum levels of Gas6 ranged from
33–95 ng/ml in active SLE patients and ranged from 15.5–
28.5 ng/ml in inactive SLE patients. These two ranges are away
from each other and both are self-discriminated. Values
>28.5 ng/ml and <33 ng/ml can be considered best cutoff
for discriminating active from those of inactive with 100%
for all criteria (diagnostic speciﬁcity, diagnostic sensitivity,
negative predictive value, positive predictive value and
efﬁcacy).4. Discussion
Gas6 is a cell survival, proliferation and chemotactic factor
and also a recognition bridge between phagocytes and apopto-
tic cells. Gas6 is present at a low concentration in plasma;
however, it can be released by endothelial cells and leukocytes
during inﬂammatory conditions [17]. Soluble Axl is the recep-
tor that binds Gas6. It has an immune-regulatory role through
modulating macrophage activation following an initial
immune stimulus [18].
Table 3 Comparison of serum levels of Gas6 and sAxl in SLE patients and healthy controls, active and inactive SLE patients and SLE
patients with and without lupus nephritis.
Parameter Gas6 (ng/ml) Median (25th–75th) percentiles p value sAxl (ng/ml)
Median (25th–75th) percentiles
p value
SLE patients (n= 50) 35 (26.5–49) <0.001 50 (24.1–103.8) 0.001
Control (n= 40) 4.5 (3–9) 0.7 (0.3–0.9)
Active patients (n= 32) 46 (37–64.6) <0.001 45 (18–121.3) 0.502
Inactive patients (n= 18) 23 (20.9–26.5) 50 (36.3–71.3)
Lupus nephritis (n= 25) 49 (39.5–76.5) <0.001 50 (21.3–130) 0.696
Kidney sparing (n= 25) 26.5 (22–33) 50 (25–65)
SLE: systemic lupus erythematosus; Gas6: Growth arrest-speciﬁc protein 6; sAxl: Soluble forms of Axl.
Figure 1 Comparison of serum concentrations of Gas6 and sAxl
between inactive and active SLE subgroups.
Figure 2 Comparison of serum concentrations of Gas6 and sAxl
between lupus nephritis and kidney sparing SLE subgroups.
Table 4 Correlations of serum Gas6 and sAxl levels in SLE
patients with laboratory data and SLEDAI.
Parameter r (p value) Gas6 (ng/ml) sAxl(ng/ml)
ESR (mm/h) 0.89 (<0.001) 0.14 (0.35)
Creatinine (mg/dl) 0.71 (<0.001) 0.03 (0.86)
Protein/creatinine 0.89 (<0.001) 0.10 (0.18)
C3 (mg/dL) 0.33 (0.02) 0.04 (0.60)
C4 (mg/dL) 0.17 (0.04) 0.04 (0.64)
Anti ds-DNA titer (U/l) 0.20 (0.015) 0.02 (0.83)
SLEDAI 0.88 (<0.001) 0.23 (0.11)
Gas6 (ng/ml) – 0.15 (0.31)
ESR: erythrocyte sedimentation rate; Pr/C: protein/creatinine ratio;
C3: complement 3; C4: complement 4; SLEDAI: systemic lupus
erythematosus disease activity index; Gas6: growth arrest-speciﬁc
protein 6.
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highly signiﬁcantly increased in SLE patients compared to
healthy controls. This was in agreement with Recarte-Pelz
et al. [3] and Kim et al. [19]. The increased level of Gas6
may be explained by an increased production to promote the
clearance of apoptotic bodies that are increased in SLE
patients. In in vitro studies, Gas6 stimulates macrophage
uptake of phosphatidyl serine liposomes which is blocked by
the soluble extracellular domain of Axl (sAxl) [20]. Therefore,
the high serum levels of Gas6 in SLE patients may be a result
of a feedback loop induced by defective apoptotic bodies’
uptake as a corrective mechanism of the immune system to
enhance not only the apoptotic bodies’ clearance but also to
hold back the activation of excessive inﬂammatory response
by the uncleared apoptotic bodies [19]. These results may give
evidence to the possibility that the high serum levels of soluble
form of Axl receptor may act as a blocker of macrophage and
dendritic cells uptake of apoptotic bodies through the Gas6/
membrane bound Axl. This defect in clearance of apoptotic
bodies results in the accumulation of apoptotic debris. It cre-
ates a viscous cycle producing further auto antibodies resulting
in marked inﬂammation in SLE [21,22]. In contrast to ourresults, Gheita et al. showed that the level of Gas6 was signif-
icantly reduced and its sAxl receptor increased compared to
the control. This decrease in Gas6 was explained by its
consumption in the apoptotic processes in SLE while the
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the macrophage pool by apoptotic debris that may increase its
expression and shedding [23]. On the other hand, other studies
revealed that the plasma concentrations of Gas6 were almost
identical between SLE patients and matched controls [17,21].
This was explained by that almost all Gas6 present in healthy
subjects is bound by soluble Axl. This may explain why there is
actually little free Gas6 present in either normal controls or
SLE patients serum [24] although the extent to which their
ELISA can detect Axl-bound Gas6 has not been tested [21].
In the present study, serum Gas6 levels showed highly sig-
niﬁcant increase among active SLE patients compared to inac-
tive SLE patients. This was supported by the signiﬁcant
positive linear correlation between serum Gas6 levels and SLE-
DAI in many studies [3,19,21,25]. SLE is characterized by
inﬂammatory vascular damage whereby the endothelial cells
are affected. Although Gas6 is present in a low concentration
in plasma, it can be released by endothelial cells and leukocytes
during inﬂammatory conditions. Gas6 promotes EC activation
and participates in the interactions between ECs, platelets, and
leukocytes during inﬂammation [14]. Moreover, Gas6 has been
shown to decrease the levels of secreted proinﬂammatory cyto-
kines by DCs. The increased levels of Gas6 in active SLE
patients compared to inactive patients are mostly referred to
the increase in its down regulatory role in inﬂammation which
becomes more prominent during periods of disease activity [3].
So, Gas6 signaling may have several effects, related to both the
initiation of inﬂammation and the regulation of established
inﬂammation [21]. In contrast to the present study, other stud-
ies did not ﬁnd a signiﬁcant difference in Gas6 levels among
active and inactive groups [26,27] though they found a trend
of increased levels of Gas6 among certain presentations
assessed in the SLEDAI score like in the patients with a history
of neurological disorder and hematological ﬂares [17].
Our results also showed no signiﬁcant difference in the
serum sAxl levels between active and inactive SLE patients.
Also, there was no signiﬁcant correlation between sAxl and
SLEDAI. This was in agreement with Recarte-Pelz et al. [3].
On the other hand, Ekman et al. [21] reported a signiﬁcant cor-
relation between sAxl and SLEDAI score. It is possible that
sAxl is correlated only indirectly with the disease activity,
and thus this correlation is lost in some populations [3].
Most likely, the differences among studies are due to the
intrinsic heterogeneity of the populations in each case.
Another possible source of heterogeneity is the effect of spe-
ciﬁc genetic factors on plasma concentrations of Gas6 and
sAxl. Different populations are likely to present differences
in the genetic distribution of the alleles responsible for sAxl
and Gas6 expression. This could be reﬂected in the plasma
concentrations of the proteins under study. Indeed certain
Gas6 variants showed considerable differences between popu-
lations from Europe and Asia [28,29].
Some studies have indicated that speciﬁc traits of SLE eval-
uated in SLEDAI, such as nephritis [21,25] or neurologic dis-
order [17], affect the values of Gas6 or sAxl receptors. The
focus of the present study was to elucidate the relation between
both serum Gas6 and sAxl and lupus renal affection. A highly
signiﬁcant increase of serum Gas6 among the lupus nephritis
group was demonstrated. However, sAxl failed to show any
signiﬁcant difference between the two groups. Ekman et al.
showed that serums Gas6 as well as sAxl were signiﬁcantly
higher in patients with lupus nephritis than in patients withoutnephritis [21]. Interestingly, Gas6 and Axl have been impli-
cated to be important in experimental glomerulonephritis
(GN) in mice, as well as diabetic and nephrotoxic nephritis.
Gas6/ mice were protected in experimental glomerulone-
phritis and nephrotoxic nephritis, and those results suggested
that Gas6 could be important in inﬂammation of experimental
glomerulonephritis and nephrotoxic nephritis [30,31]. Gas6
may have a special role in renal pathophysiology especially
in SLE. Gas6 roles in vascular biology through activation of
receptor tyrosine kinases resulting in vascular smooth muscle
cell proliferation, adhesion and migration and inhibition of
leukocytes adhesion to endothelial cells in the presence of
chemoattractants may add reasonable proof for this postula-
tion [27].
In conclusion, increased serum Gas6 and sAxl levels in SLE
patients may be due to defect in the clearance of apoptotic
bodies; one of the possible triggers of autoimmune reaction
in SLE patients. Serum Gas6 can be used as an activity marker
and gives also an idea about the severity of renal involvement.
On the other hand, serum sAxl levels had no signiﬁcant asso-
ciation with disease activity or renal involvement. So, screen-
ing of activity of SLE and severity of renal involvement is
recommended by measuring serum Gas6 for better assessment
and management of the disease.Conﬂict of interest
The authors declare no conﬂict of interest.
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